CollPlant Biotechnologies Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company developing products based on recombinant human collagen produced in genetically engineered tobacco plants, with a focus on medical aesthetics and 3D bioprinting.
What they do
CollPlant develops and commercializes products based on its proprietary recombinant human collagen (rhCollagen) technology. The company operates in two main areas: dermal and soft tissue fillers (in partnership with Allergan, an AbbVie company, under a 2021 development and global commercialization agreement) and 3D bioprinting of tissues and organs. CollPlant's products are intended for tissue repair and aesthetics, and the company also has subsidiaries CollPlant Ltd. and CollPlant Inc.
Revenue drivers
- Dermal and soft tissue filler products — Under the 2021 agreement with Allergan (AbbVie), CollPlant is developing filler products; revenue from this collaboration appears limited, as total annual revenue was only $2.4M in 2025.
- Other product sales and services — Revenue has been volatile: $15.6M in 2021, $299K in 2022, $11.0M in 2023, $515K in 2024, and $2.4M in 2025, indicating no consistent recurring revenue stream.
Recent performance
In 2025, CollPlant reported annual revenue of $2.4M, up from $515K in 2024, but still far below the 2021 peak of $15.6M. Net loss narrowed to $-11.5M in 2025 from $-16.6M in 2024, and diluted EPS improved to $-0.94 from $-1.45. Operating cash flow was negative at $-9.4M in 2025. As of December 31, 2025, the company had cash and equivalents of $5.6M, total assets of $10.8M, and shareholder equity of $6.1M.
Strategy
CollPlant is focused on advancing its rhCollagen-based products in medical aesthetics and 3D bioprinting. The company is developing dermal and soft tissue fillers with Allergan (AbbVie) under a global commercialization agreement. It also continues to invest in R&D for tissue and organ bioprinting, aiming to leverage its plant-based collagen platform. The company is prioritizing regulatory and clinical development of its product pipeline.
Risks
- Revenue volatility — Annual revenue has swung from $15.6M (2021) to $299K (2022) to $11.0M (2023) to $515K (2024), indicating an unstable revenue base.
- Cash runway — With only $5.6M in cash and operating cash flow of -$9.4M in 2025, the company may need to raise additional capital to fund operations.
- Partner dependence — A significant portion of the business depends on the Allergan (AbbVie) agreement; any delay or termination could materially impact CollPlant.
- Regulatory and clinical risk — As a development-stage company, its products face regulatory approval and clinical trial risks, with no guarantee of successful commercialization.
Outlook
Management's outlook is not explicitly stated in the provided excerpts, but the company continues to advance its partnership with Allergan (AbbVie) and invest in its rhCollagen platform. The company is likely to focus on achieving development milestones and managing its cash position. Given the low revenue base, near-term profitability is not expected.